Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficient CRISPR/Cas9 nickase-mediated genome editing in an in vitro model of mucopolysaccharidosis IVA

18 May 2022

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to Lysosomal Storage Disorders Research
Share to Retinal Development and Disorders

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 35581402
DOI: 10.1038/s41434-022-00344-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficient CRISPR/Cas9 nickase-mediated genome editing in an in vitro model of mucopolysaccharidosis IVAPMID 35581402Read ↗

In vivo genome editing of mucopolysaccharidosis I mice using the CRISPR/Cas9 systemSemantic proximity Read ↗

An Insight into Modern Targeted Genome-Editing Technologies with a Special Focus on CRISPR/Cas9 and its ApplicationsSemantic proximity Read ↗

Improvements of nuclease and nickase gene modification techniques for the treatment of genetic diseasesSemantic proximity Read ↗

CRISPR/Cas based gene editing: marking a new era in medical scienceSemantic proximity Read ↗

CRISPR-Cas9-mediated gene editing in human MPS I fibroblasts.Semantic proximity Read ↗

CRISPR/Cas9 a simple, inexpensive and effective technique for gene editingSemantic proximity Read ↗

Making gene editing a therapeutic realitySemantic proximity Read ↗

Neuromuscular disease: CRISPR/Cas9 gene-editing platform corrects mutations associated with Duchenne muscular dystrophy.Semantic proximity Read ↗

CRISPR/Cas9 for the treatment of haematological diseases: a journey from bacteria to the bedsideSemantic proximity Read ↗

Clinical trials and promising preclinical applications of CRISPR/Cas gene editingSemantic proximity Read ↗

The Control and Trust of CRISPR / Cas9 Genome Altering for Clinical Application with Gene Treatment and Treatment of Hereditary DiseasesSemantic proximity Read ↗

Genome Editing for MucopolysaccharidosesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.